Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RU90395 is a synthetic small molecule inhibitor belonging to the class of organic compounds known as dipeptides. It has been studied primarily as an experimental agent targeting the proto-oncogene tyrosine-protein kinase Src, a non-receptor tyrosine kinase involved in cellular signaling pathways related to cancer and other proliferative diseases. The compound acts by inhibiting Src kinase activity, thereby potentially interfering with downstream signaling events that promote cell growth and survival. Its molecular formula is C35H36FN3O9 and it has a molecular weight of approximately 661.7 g/mol[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RU90395.